as 08-29-2025 4:00pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | MIDDLETOWN |
Market Cap: | 968.5M | IPO Year: | 2017 |
Target Price: | $20.00 | AVG Volume (30 days): | 444.0K |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.98 | EPS Growth: | N/A |
52 Week Low/High: | $9.03 - $17.70 | Next Earning Date: | 08-07-2025 |
Revenue: | $122,867,000 | Revenue Growth: | 95.94% |
Revenue Growth (this year): | 107.76% | Revenue Growth (next year): | 2.35% |
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
Simply Wall St.
4 months ago
Simply Wall St.
4 months ago
GlobeNewswire
4 months ago
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.